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Abstract: The peripheral blood levels of TNF α and its soluble receptors were studied in 
39 patients with malignant and benign adrenal tumors treated by adrenalectomy. The 
concentrations of TNF α were significantly elevated in patients with malignant tumors of 
the adrenal cortex and in patients with Conn's syndrome compared to control. In patients 
with non-functioning adenomas and pheochromocytomas, TNF α levels were similar to 
those detected in the control. In subjects with myelolipomas, the serum concentration of 
TNF α was lower compared to the control. After adrenalectomy, the levels of TNF α were 
decreased in patients with malignant tumors and in patients with Conn's syndrome, non-
functioniong adenomas and pheochromocytomas compared to the concentration before 
surgery. The serum concentrations of soluble receptors of TNF α did not differ among 
different patient groups and compared to the control. After adrenalectomy, the blood 
concentrations of TNF α R1 and TNF α R2 were decreased in patients with Conn's 
syndrome. However, to confirm practicality of the evaluation of TNF α and its soluble 
receptors in differential diagnosis in patients with adrenal tumors, a larger study group  
is needed.  
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Modern imaging modalities lead to frequent detection of adrenal masses. Most of them are 
incidental findings. Although the majority of adrenocortical and adrenomedullary tumors are benign, 
there are no clinical and laboratory markers to distinguish most of them from malignant tumors [1,2]. 
The molecular mechanisms underlying the pathogenesis of these tumors have been recently unraveled. 
Because prognoses and surgical methods for adrenocortical adenomas and adrenal carcinomas are 
vastly different it is important to accurately differentiate the two tumor types. However, the study on 
the serum concentration of tumor necrosis factor α (TNF α) and its soluble receptors (TNF α R1 and 
TNF α R2) have not been performed in patients with adrenal tumors so far.  
TNF α is a pleiotropic cytokine that plays a central role in inflammation and apoptosis. It modifies 
the inflammatory reactions and immune reactions in response to injury and infection [3]. TNF α plays 
also a necessary and beneficial role as mediator of host resistance to infection and tumor formation. 
Moreover, overproduction of TNF α or its overexpression can lead to a variety of pathologic 
conditions including wasting, systemic toxicity and septic shock. TNF α acts via two types of receptors 
(TNF α R1, TNF α R2), located on the cell surface. Type one of the TNF α receptor is involved in 
apoptosis. The physiological role of the type two TNF α receptor is unknown, but this type of receptor 
is also probably involved in apoptosis [4,5]. The soluble forms of these receptors arise as a result of 
shedding of the extracellular domain of the receptors and are present in low concentrations in serum 
and urine of healthy subjects [6,7].  
The aim of the study was to evaluate the serum concentrations of TNF α and its soluble receptors in 
patients with malignant and benign adrenal tumors treated by adrenalectomy. We evaluated usefulness 
of these peptides as the laboratory markers in differential diagnosis. 
2. Materials and Methods 
The study group was composed of 39 subjects [28 females aged 25-82 (53.68 ± 16.60; x ± SD) and 
11 males aged 46-74 (56.45 ± 7.55)]. Seven patients with malignant cortical tumors, seven patients 
with Conn's syndrome, 10 patients with non-functioning adrenal adenomas, 12 patients with 
pheochromocytomas and three patients with myelolipomas (according to pathology data) were studied. 
The clinical diagnosis of the malignant tumors was suspected in patients with weight loss, high serum 
concentration of dehydroepiandrosterone sulfate and irregular, large (usually with a diameter greater 
than 6 cm) mass found by computer tomography imaging. The diagnosis of the Conn's syndrome was 
based on elevated level of plasma aldosterone, low level of plasma renin and an aldosterone/renin ratio 
of greater than 5.4. The diagnosis of pheochromocytoma was suspected in patients with poorly 
controlled hypertension associated with bouts of sweating, headache, palpitations, a high serum 
concentration of chromogranin A and a high level of metanephrins in urine. In patients with non-
functioning adenomas and myelolipomas, the tumors were incidentally found during computer 
tomography imaging.  
The adrenal tumors were surgically removed. All the investigations were performed one day prior to 
surgical treatment and one month after adrenalectomy. The clinical diagnosis was confirmed by 




The control group was composed of 10 healthy subjects (six females and four males) aged 36-60  
(49.5 ± 8.38). The presence of adrenal tumor was excluded on the basis of physical examination, 
laboratory tests and ultrasound examination of the abdomen. All patients and control group were 
included in the study only after giving informed consent. The study was approved by the Local Ethical 
Committee.  
The concentration of TNF α and its soluble receptors were measured by enzyme immunoassay 
(ELISA) (R&D Systems, USA). The intra-assay precision for TNF α was 4.67%, for TNF α R1 – 
4.43%, and for TNF α R2 was 3.53%. The inter - assay precision for TNF α was 5.8%, for TNF α R1 – 
6.1%, and for TNF α R2 was 4.07%. The statistical analysis was performed using the non - parametric 
Kruskal-Wallis test and Wilxocon test. A p-value of less than 0.05 was considered statistically 
significant. 
3. Results 
The concentrations of TNF α, TNF α R1 and TNF α R2 before surgery and after surgery are 
presented in Figures 1-6. The mean (x  ± SD) concentration of TNF α in the control group was   
12.09 ± 4.31 pg/mL, the mean concentration of TNF α R1 was 1,479.2 ± 388.23 pg/mL, and the mean 
concentration of TNF α R2 was 2,456.7 ± 521.12 pg/mL. The concentration of TNF α was 
significantly elevated in patients with malignant tumors of the adrenal cortex, compared to the control  
(30.04 ± 13.28 pg/mL vs. 12.09 ± 4.31 pg/mL; p < 0.05), and in patients with Conn's syndrome, 
compared to the control (16.22 ± 1.11 pg/mL vs. 12.09 ± 4.31 pg/mL; p < 0.05). The highest levels of 
TNF α in patients with malignant tumors of the cortex were noted. In patients with non-functioning 
adenomas and pheochromocytomas, TNF α levels were not significantly different from those of the 
control, (p > 0.05) and were respectively 11.0 ± 2.03 pg/mL; 9.14 ± 4.58 pg/mL. In patients with 
myelolipomas, the serum concentration of TNF α was lower, compared to control (2.06 ± 3.58 pg/mL 
vs. 12.09 ± 4.31 pg/mL; p < 0.05) (Figure 1). 
After adrenalectomy, the levels of TNF α were lower in patients with malignant tumors   
(8.60 ± 4.35 pg/mL vs. 30.4 ± 13.28 pg/mL; p  < 0.02), and in patients with Conn's syndrome   
(8.07 ± 3.03 pg/mL vs. 16.22 ± 1.11 pg/mL; p < 0.02), non-functioning adenomas (4.77 ± 3.91 pg/mL 
vs. 11.0 ± 2,03 pg/mL; p < 0.01) and pheochromocytomas (1.95 ± 3.23 pg/mL vs. 9.14 ± 4.58 pg/mL;  
p < 0.01) than before surgery (Figure 2). The serum concentration of soluble receptors of TNF α did 
not differ among different patient groups or the control (Figures 3 and 5). After adrenalectomy, the 
serum concentration of TNF α R1 and TNF α R2 decreased in patients with Conn's syndrome   
(1365.86 ± 156.51 vs. 2309.43 ± 736.86 pg/mL; p  < 0.02 and 2587.71 ± 406.81 pg/mL vs.  
3652.14 ± 956.62 pg/mL; p < 0.05 respectively) (Figures 4 and 6).  
No significant correlations between the size of the tumors and the serum level of TNF α and its 
receptors were found. 




Figure 1. Concentrations of TNF α (pg/mL) in peripheral blood of patients and control 
(median and range). 
 
 
Figure. 2. Concentrations of TNF α (pg/mL) in peripheral blood studied groups of patients 
before and after surgery (median and range). 
 




Figure. 3. Concentrations of TNF R1 α (pg/mL) in peripheral blood of studied groups of 
patients and control (median and range). 
 
 
Figure 4. Concentrations of TNF R1 α (pg/mL) in peripheral blood of studied groups of 
patients before and after surgery (median and range). 
 
 




Figure 5. Concentrations of TNF R2 α (pg/mL) in peripheral blood of studied groups of 
patients and control (median and range). 
 
 
Figure 6. Concentrations of TNF R2 α (pg/mL) in peripheral blood of studied groups 
before and after surgery (median and range). 
 
4. Discussion  
TNF α is a transmembrane protein described originally as a protein which causes the haemorrhagic 
necrosis of experimental tumors [8]. Further studies revealed that TNF α possesses proinflammatory 
activity and plays a key role in apoptosis [9-12]. A low level of TNF α and its receptors may increase 
susceptibility to infections [13]. TNF α is also probably involved in development of lymphoid   




The role of TNF α in pathogenesis of malignant tumors is not clearly understood. Mocellin and  
Nitti [15] suggest that TNF α may represent one of the molecular links between chronic inflammation 
and further development of malignant tumors. Leibovich et al. [16] revealed that TNF α may promote 
angiogenesis but others [17] did not confirm the proangiogenic activity of TNF α. Schweigerer et al. 
[17] assessed the influence of TNF α on the proliferation of endothelial cells derived from blood 
vessels of the brain and adrenal cortex. In both types of these cells, TNF α decreased the proliferative 
activity of endothelial cells. 
TNF α acts also as a paracrinal and autocrinal regulator of the growth and development of the 
adrenocortical cells. Call et al. [18] revealed that bovine adrenal glands secrete TNF α and IL-6. They 
also proved, using immunoassay techniques, that the glomerular zone of the adrenal cortex is the site 
of the greatest synthesis of TNF α. The increased level of TNF α in our study in patients with Conn's 
syndrome may confirm that the glomerular zone of the adrenal cortex mainly secretes TNF α. The 
secretion of TNF α by human adrenal glands confirmed the studies of González-Hernández et al. 
[19,20] and Päth et al. [21]. It is also known that TNF α has an influence on synthesis and secretion of 
steroid hormones in adrenal cortex [22]. Moreover, that elevated levels of TNF α occur in the blood of 
patients with malignant tumors. Cimino et al. [23] observed an increased level of TNF α (and also 
interleukin 2 and soluble forms of IL-2 receptors) in the blood of patients with acute leukemia. 
Elevated levels of TNF α were also confirmed in the peripheral blood of patients with melanoma [24], 
renal carcinoma [25] and pancreas carcinoma [26]. 
The results of our study showed the highest level of TNF α in patients with malignant tumors 
(primary adrenocortical carcinoma and metastatic tumors). It may be due to activation of the 
immunological system and cytokine net in patients with malignant tumors. The elevated levels of TNF 
α in patients with malignant tumors may be also due to activation of angiogenesis and overexpression 
of TNF α in the transformed cells. Interferon γ is known as the most important factor to increase the 
expression of TNF α. The regulation of the expression is at the transcriptional level [27]. It has also 
been proven that elevated levels of TNF α may lead to overexpression of integrins and adhesive 
molecules [28]. Guardiola-Serrano et al. [29] assessed the influence of TNF α on the expression of 
ZC3H10 (zinc finger protein) and GRHL-3 (grainyhead-like 3) in breast cancer cell lines (MCF-7). 
Expression of these proteins was increased after addition of TNF α to the incubation medium of the 
cells in vitro. However, ZC3H10 acts as an antagonist of cell growth in vitro, but GRHL-3 stimulates 
the migration of the endothelial cells. 
In our patients with malignant tumors of the adrenal cortex, in patients with Conn's syndrome and in 
patients with non-functioning adenomas and pheochromocytomas the concentration of TNF α was 
decreased after adrenalectomy. These results may be due to elimination of the tumor, which was the 
main local source of TNF α. 
The role of the soluble receptors of TNF α in the pathogenesis of adrenal tumors is unknown. 
Elevated levels of these receptors were found in the amniotic fluid of pregnant women [30,31], in the 
serum and plasma of patients with HIV [32] and patients with malignant tumors [33]. Some authors 
suggest that soluble forms of TNF α receptors may bind TNF α and inactivate this molecule. On the other 
hand, these forms of TNF α receptors can stabilize the TNF α molecule at low concentrations of TNF α [6]. 
The results of our study revealed that the concentration of soluble forms of TNF α receptors did not 




soluble forms of TNF α decreased in patients with Conn's syndrome. It could be argued that the soluble 
forms of TNF α receptors are also involved in the process of tumorigenesis. The low level of TNF α 
and high level of soluble forms of TNF α receptors in patients with myelolipoma may confirm the 
hypothesis that soluble forms of these receptors inactivate this molecule. However, such a small group 
(3 patients) is not sufficient to draw any significant conclusions. 
To confirm practicality of the evaluation of TNF α and its soluble receptors in differential diagnosis 
in patients with adrenal tumors, a large study group is needed. The evaluation of the concentration of 
numerous cytokines in the blood has been used only in the clinical studies so far. To take advantage of 
these molecules in clinical practice, further studies are needed and clinical examinations, laboratory 
tests and imaging techniques will still be the most important means of diagnosing patients with adrenal 
tumors. 
5. Conclusions 
TNF α and its soluble receptors appear to be involved in adrenal gland oncogenesis. The peripheral 
blood concentrations of this cytokines before surgery may be useful for the discrimination between 
malignant and benign adrenal tumors. 
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